AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25785968 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg mongersen
Number of subjects: 0
Study 25785968 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg mongersen
Number of subjects: 0
Study 25785968 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mongersen
Number of subjects: 0
Study 25785968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24251826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 6
Study 24251826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 21724462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus rituximab
Number of subjects: 676
Study 21724462 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 676
Study 19588654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cabbage leaves
Number of subjects: 0
Study 19588654 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate hot and cold compresses
Number of subjects: 0
Study 19588654 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17542203 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching agent (Opalescence, OPA)
Number of subjects: 40
Study 17542203 — intervention group
Group type: COMPARATOR
Intervention: Placebo agent (PLA)
Number of subjects: 40
Study 15366527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution (Periogard) mouth rinse
Number of subjects: 60
Study 15366527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride solution (Cepacol)
Number of subjects: 60
Study 15366527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution (Periogard)
Number of subjects: 60
Study 12079502 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite barrier bedding
Number of subjects: 47
Study 12079502 — intervention group
Group type: COMPARATOR
Intervention: Placebo bedding
Number of subjects: 47
Study 9833852 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (zidovudine 300 mg twice daily, lamivudine 150 mg twice daily, ritonavir 600 mg twice daily)
Number of subjects: 15
Study 7862842 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 10
Study 7862842 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 10
Study 7862842 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil + Midazolam
Number of subjects: 10
Study 7862842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7862842 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 10
Study 2476608 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 40
Study 2476608 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study 241192 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzquinamide (0.7 mg/kg)
Number of subjects: 12
Study 241192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30981791 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater EMR (UEMR)
Number of subjects: 210
Study 30981791 — intervention group
Group type: COMPARATOR
Intervention: Conventional EMR (CEMR)
Number of subjects: 210
Study 29074303 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (P)
Number of subjects: 6
Study 29074303 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine (1 μg kg−1, PLD)
Number of subjects: 6
Study 29074303 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine (2 μg kg−1, PHD)
Number of subjects: 6
Study 26446165 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous bolus of methylprednisolone
Number of subjects: 0
Study 26446165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23377389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 322
Study 23377389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 22133340 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional speech alert messages
Number of subjects: 38
Study 22133340 — intervention group
Group type: COMPARATOR
Intervention: High rate of false alarms
Number of subjects: 38
Study 19010447 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based self-management program (5 sessions with a nurse trained in MI counseling)
Number of subjects: 22
Study 19010447 — intervention group
Group type: COMPARATOR
Intervention: Control group (received courtesy calls)
Number of subjects: 22
Study 17274922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2.5 years followed by aromatase inhibitor for 2.5 years
Number of subjects: 0
Study 17274922 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of aromatase inhibitor
Number of subjects: 0
Study 15265851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menaquinone) 45 mg/d
Number of subjects: 40
Study 15265851 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptomatic therapy for ascites and dietary advice)
Number of subjects: 40
Study 12403915 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 0
Study 12403915 — intervention group
Group type: COMPARATOR
Intervention: RCTs from Japan
Number of subjects: 0
Study 12403915 — intervention group
Group type: COMPARATOR
Intervention: Case-control/cohort studies from Japan
Number of subjects: 0
Study 9615868 — intervention group
Group type: EXPERIMENTAL
Intervention: VOL
Number of subjects: 22
Study 9615868 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS
Number of subjects: 22
Study 9615868 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 8127562 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial keratotomy surgery
Number of subjects: 328
Study 2631000 — intervention group
Group type: EXPERIMENTAL
Intervention: Igel 67 (Prima)
Number of subjects: 10
Study 2631000 — intervention group
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb 70
Number of subjects: 10
Study 2631000 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed eye wear
Number of subjects: 10
Study 2631000 — intervention group
Group type: COMPARATOR
Intervention: Open eye wear
Number of subjects: 10
Study 791586 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg azapropazone daily for 2 weeks
Number of subjects: 15
Study 791586 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg naproxen daily for 2 weeks
Number of subjects: 15
Study 791586 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 15
Study 30847805 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®)
Number of subjects: 0
Study 30847805 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat administration of triamcinolone acetonide ER
Number of subjects: 0
Study 30847805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30847805 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide crystalline suspension (CS)
Number of subjects: 0
Study 27807771 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week restriction
Number of subjects: 108
Study 27807771 — intervention group
Group type: COMPARATOR
Intervention: 6-week restriction
Number of subjects: 108
Study 26206737 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeR pacing algorithm
Number of subjects: 373
Study 26206737 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing with a long atrioventricular delay (250 ms)
Number of subjects: 373
Study 24569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid
Number of subjects: 150
Study 24569324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 21865154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (specific details not provided)
Number of subjects: 333
Study 21865154 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies (hand distributed letters, flyers, word of mouth)
Number of subjects: 333
Study 21865154 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment process
Number of subjects: 333
Study 19144173 — intervention group
Group type: COMPARATOR
Intervention: Long-acting anticholinergics
Number of subjects: 26786
Study 19144173 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 26786
Study 19144173 — intervention group
Group type: COMPARATOR
Intervention: Long-acting bronchodilators alone
Number of subjects: 26786
Study 19144173 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 26786
Study 19144173 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and combination treatment
Number of subjects: 26786
Study 17461719 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg twice-daily or 800/200 mg once-daily with gastric acid-reducing agents
Number of subjects: 228
Study 17461719 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir 400/100 mg twice-daily or 800/200 mg once-daily without gastric acid-reducing agents
Number of subjects: 228
Study 15610362 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose birch pollen exposure during pregnancy
Number of subjects: 387
Study 15610362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose birch pollen exposure during pregnancy
Number of subjects: 387
Study 15610362 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal birch sensitization
Number of subjects: 387
Study 15610362 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pollen allergy
Number of subjects: 387
Study 15610362 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma symptoms and sensitization to birch
Number of subjects: 387
Study 11310807 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (2 g/200 mg/8 hr)
Number of subjects: 378
Study 11310807 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (1 g/24 hr)
Number of subjects: 378
Study 11310807 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 378
Study 11310807 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 378
Study 9153524 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 9
Study 9153524 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 9
Study 9153524 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 9
Study 8389105 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 (200 micrograms/puff, total dose 1,600 micrograms)
Number of subjects: 10
Study 8389105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (propellant alone)
Number of subjects: 10
Study 8389105 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219
Number of subjects: 10
Study 8389105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3818718 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 55
Study 3818718 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 55
Study 29374679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw
Number of subjects: 1128
Study 29374679 — intervention group
Group type: COMPARATOR
Intervention: X-Bolt Dynamic Hip Plating System
Number of subjects: 1128
Study 27472878 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus L.
Number of subjects: 35
Study 27472878 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 35
Study 25300433 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST intervention - systematic and progressive practice of fast squatting and stepping exercises
Number of subjects: 60
Study 25300433 — intervention group
Group type: COMPARATOR
Intervention: Active control - conventional physiotherapy directed at improving balance and mobility that includes no targeted fast movement training
Number of subjects: 60
Study 25300433 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST intervention
Number of subjects: 60
Study 22325963 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB) with 0.2% ropivacaine via indwelling catheter for 72 hours
Number of subjects: 16
Study 22325963 — intervention group
Group type: COMPARATOR
Intervention: Multimodal periarticular soft tissue injection
Number of subjects: 16
Study 22325963 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 16
Study 22325963 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcomes
Number of subjects: 16
Study 20052813 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective approach (group SEL) - only the nerves involved in the surgical field were injected
Number of subjects: 414
Study 20052813 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-nerve stimulation technique (group TNS)
Number of subjects: 414
Study 20052813 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective approach (group SEL)
Number of subjects: 414
Study 17280925 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ml fentanyl 0.05 mg/ml
Number of subjects: 40
Study 17280925 — intervention group
Group type: COMPARATOR
Intervention: 0.4 ml mepivacaine with epinephrine 1:200,000
Number of subjects: 40
Study 15663351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 or 2mg once daily
Number of subjects: 404
Study 15663351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 0.5 or 1mg once daily
Number of subjects: 404
Study 15663351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1mg once daily
Number of subjects: 404
Study 15663351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (monotherapy and combination therapy)
Number of subjects: 404
Study 15663351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline for 12 months
Number of subjects: 404
Study 12360588 — intervention group
Group type: EXPERIMENTAL
Intervention: Transluminal balloon coronary angioplasty (TBCA) or stenting
Number of subjects: 87
Study 9988823 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg)
Number of subjects: 55
Study 9988823 — intervention group
Group type: COMPARATOR
Intervention: Control (without zinc)
Number of subjects: 55
Study 7502571 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR1-pacing (70-110 bpm)
Number of subjects: 20
Study 7502571 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR2-pacing (70-130 bpm)
Number of subjects: 20
Study 7502571 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR1-pacing (70-110 bpm) in Weber class D patients
Number of subjects: 20
Study 7502571 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR2-pacing (70-130 bpm) in Weber class C patients
Number of subjects: 20
Study 1575174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg
Number of subjects: 388
Study 1575174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 50 mg
Number of subjects: 388
Study 1575174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 100 mg
Number of subjects: 388
Study 1575174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 150 mg
Number of subjects: 388
Study 1575174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 3893441 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 189
Study 3893441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 30169375 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent pictorial drug choice task (smoking vs. not smoking)
Number of subjects: 81
Study 30169375 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent pictorial drug choice task (alcohol vs. food)
Number of subjects: 81
Study 26390226 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 30
Study 26390226 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 30
Study 26327217 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-assessment group
Number of subjects: 731
Study 26327217 — intervention group
Group type: COMPARATOR
Intervention: Clinic follow-up group
Number of subjects: 731
Study 26327217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 731
Study 23897964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 201
Study 23897964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 21046236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet FO (fish oil)
Number of subjects: 6
Study 21046236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet LO (linseed oil)
Number of subjects: 6
Study 21046236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet SO (soybean oil)
Number of subjects: 6
Study 21046236 — intervention group
Group type: COMPARATOR
Intervention: Diet PO (peanut oil)
Number of subjects: 6
Study 21046236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet PL (pork lard)
Number of subjects: 6
Study 21046236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet APO (arachidonic acid and peanut oil)
Number of subjects: 6
Study 21046236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets with EPA and DHA
Number of subjects: 6
Study 18773262 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% nipradilol, twice daily for 3 years
Number of subjects: 146
Study 18773262 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol ophthalmic solution, twice daily for 3 years
Number of subjects: 146
Study 16523203 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley kernels
Number of subjects: 15
Study 16523203 — intervention group
Group type: COMPARATOR
Intervention: WWB
Number of subjects: 15
Study 14669936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplement (18 mg beta‐carotene, 900 mg vitamin C, 90 mg vitamin E)
Number of subjects: 12
Study 14669936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14669936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplement
Number of subjects: 12
Study 10844841 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 21
Study 10844841 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 21
Study 10844841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 21
Study 8705154 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg intra-articular morphine in 15 ml isotonic saline
Number of subjects: 60
Study 8705154 — intervention group
Group type: COMPARATOR
Intervention: 3 mg intravenous morphine in 10 ml isotonic saline
Number of subjects: 60
Study 2371491 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg/day for 3 days
Number of subjects: 0
Study 2371491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 453340 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory electromyographic (EMG) feedback applied at 6, 25, 30, 49, and 54 hours after exercise.
Number of subjects: 36
Study 453340 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching applied to the exercised arm at 6, 25, 30, 49, and 54 hours after exercise.
Number of subjects: 36
Study 453340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 36
Study 29610222 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL) followed by photorefractive keratectomy (PRK) after 6 months
Number of subjects: 44
Study 29610222 — intervention group
Group type: COMPARATOR
Intervention: PRK alone
Number of subjects: 44
Study 28176907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg
Number of subjects: 430
Study 28176907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 µg
Number of subjects: 430
Study 28176907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 24989711 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion‐dependent β‐thalassemia patients
Number of subjects: 0
Study 24989711 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24989711 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with evident heart disease
Number of subjects: 0
Study 24989711 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with β‐thalassemia
Number of subjects: 0
Study 22420837 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-soaked antibacterial gauze-based NPWT
Number of subjects: 50
Study 22420837 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiseptic (polyhexanide solution) dressings
Number of subjects: 50
Study 22403988 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Pro‐Relief Toothpaste
Number of subjects: 150
Study 22403988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensodyne Rapid Relief Toothpaste
Number of subjects: 150
Study 22403988 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Cavity Protection Toothpaste
Number of subjects: 150
Study 19486346 — intervention group
Group type: EXPERIMENTAL
Intervention: m-TOR inhibitor sirolimus (SRL)
Number of subjects: 16
Study 19486346 — intervention group
Group type: COMPARATOR
Intervention: CNI treatment
Number of subjects: 16
Study 16855426 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (4 mg/24 h starting dose, increased by 4 mg/24 h weekly)
Number of subjects: 0
Study 16855426 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (4 mg/24 h starting dose, increased by 2 mg/24 h weekly)
Number of subjects: 0
Study 16855426 — intervention group
Group type: COMPARATOR
Intervention: Fast-titration regimen of rotigotine
Number of subjects: 0
Study 16855426 — intervention group
Group type: COMPARATOR
Intervention: Slow-titration regimen of rotigotine
Number of subjects: 0
Study 12944032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine ER (20 to 60 mg once daily)
Number of subjects: 192
Study 12944032 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 to 10 mg once daily)
Number of subjects: 192